Guinness Asset Management LTD Bristol Myers Squibb CO Transaction History

Guinness Asset Management LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	BUY	$63.71 - $70.74 $1.13 Million - $1.25 Million	17,741 Added 7.09%	267,845 $17.1 Million
Q1 2023 Apr 10, 2023	BUY	$65.71 - $74.53 $18,858 - $21,390	287 Added 0.11%	250,104 $17.3 Million
Q4 2022 Feb 02, 2023	BUY	$68.48 - $81.09 $187,498 - $222,024	2,738 Added 1.11%	249,817 $18 Million
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $625 - $369,907	-4,814 Reduced 1.91%	247,079 $17.6 Million
Q2 2022 Sep 06, 2022	SELL	$72.62 - $79.98 $12 Million - $13.2 Million	-164,622 Reduced 39.52%	251,893 $19.4 Million
Q1 2022 Apr 13, 2022	BUY	$61.48 - $73.72 $563,402 - $675,570	9,164 Added 2.25%	416,515 $30.4 Million
Q4 2021 Jan 19, 2022	BUY	$53.63 - $62.52 $1.07 Million - $1.25 Million	19,930 Added 5.14%	407,351 $25.4 Million
Q3 2021 Dec 07, 2021	BUY	$59.17 - $69.31 $3.43 Million - $4.02 Million	57,961 Added 17.59%	387,421 $22.9 Million
Q2 2021 Aug 03, 2021	BUY	$61.91 - $67.42 $332,456 - $362,045	5,370 Added 1.66%	329,460 $22 Million
Q1 2021 Apr 21, 2021	BUY	$59.34 - $66.74 $5.02 Million - $5.64 Million	84,540 Added 35.29%	324,090 $20.5 Million
Q4 2020 Jan 25, 2021	BUY	$57.74 - $65.43 $3.11 Million - $3.52 Million	53,840 Added 28.99%	239,550 $14.9 Million
Q3 2020 Oct 27, 2020	BUY	$57.43 - $63.64 $2.51 Million - $2.78 Million	43,690 Added 30.76%	185,710 $11.2 Million
Q2 2020 Jul 28, 2020	SELL	$54.82 - $64.09 $350,848 - $410,176	-6,400 Reduced 4.31%	142,020 $8.35 Million
Q4 2019 Feb 04, 2020	BUY	$49.21 - $64.19 $7.3 Million - $9.53 Million	148,420 New	148,420 $9.53 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Guinness Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Guinness Asset Management LTD with notifications on news.